Literature DB >> 3552923

The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation.

J Ludwig, R H Wiesner, K P Batts, J D Perkins, R A Krom.   

Abstract

The acute vanishing bile duct syndrome can be defined as an irreversible, rejection-related condition that affects hepatic allografts within 100 days after orthotopic liver transplantation and whose presence requires retransplantation. We have observed the acute vanishing bile duct syndrome in 5 of 48 consecutive patients (approximately 10%) who underwent orthotopic liver transplantation. In 4 cases, the condition progressed relentlessly within approximately 7 to 11 weeks after orthotopic liver transplantation from mild rejection to severe rejection to acute vanishing bile duct syndrome. A fifth patient had severe rejection in the first week and required retransplantation after 17 days because of thrombotic venoocclusive disease complicating the acute vanishing bile duct syndrome. Clinically, signs of impending acute vanishing bile duct syndrome included abrupt onset of fever and jaundice and marked elevation of serum bilirubin and alkaline phosphatase levels which persisted despite antirejection treatment. Biopsy specimens revealed destructive cholangitis (rejection cholangitis), ductopenia, and, if retransplantation was delayed, presence of noninflammatory, "burnt-out" portal tracts without bile ducts. We recommend to base the diagnosis of acute vanishing bile duct syndrome on documentation of severe ductopenia in at least 20 portal tracts which may require several consecutive needle biopsies. Rejection arteriopathy which was found in 3 of our 5 cases might have been another important diagnostic clue but could not be recognized prior to retransplantation. The pathogenesis of acute vanishing bile duct syndrome is not clear; until the condition had manifested itself, we found no qualitative differences between acute reversible and irreversible rejection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3552923     DOI: 10.1002/hep.1840070311

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Management of biliary complications after orthotopic liver transplantation: the role of endoscopy.

Authors:  Maria-C Londoño; Domingo Balderramo; Andrés Cárdenas
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

2.  Peribiliary vascular diseases in rejected livers; computer-aided three-dimensional reconstruction and morphometry.

Authors:  M Takemura; S Oguma; S Mori; M Ishii; T E Starzl; A J Demetris; T Takahasi
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

4.  Hepatitis C and bile duct loss.

Authors:  R D Goldin; N K Patel; H C Thomas
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

Review 5.  Liver transplantation--the first 25 years.

Authors:  H L Ascher
Journal:  West J Med       Date:  1988-09

Review 6.  Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.

Authors:  Sanjay K Yadav; Sanjiv Saigal; Narendra S Choudhary; Sujit Saha; Navin Kumar; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2017-05-22

7.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

Review 8.  The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?

Authors:  A J Demetris; N Murase; C P Delaney; M Woan; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 9.  Secondary sclerosing cholangitis.

Authors:  Petra Ruemmele; Ferdinand Hofstaedter; Cornelia M Gelbmann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-05       Impact factor: 46.802

Review 10.  [Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases].

Authors:  T Longerich; C Flechtenmacher; P Schirmacher
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.